Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.

[1]  L. Lund,et al.  Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry , 2018, European journal of heart failure.

[2]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[3]  F. Zannad,et al.  Interpretation of the ATHENA Trial-Caveats and Future Directions. , 2017, JAMA cardiology.

[4]  K. Anstrom,et al.  Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial , 2017, JAMA cardiology.

[5]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[6]  S. Solomon,et al.  Influence of atrial fibrillation on post‐discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial , 2017, European journal of heart failure.

[7]  C. Ronco,et al.  Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance. , 2016, International journal of cardiology.

[8]  K. Anstrom,et al.  Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. , 2016, JACC. Heart failure.

[9]  C. Parikh,et al.  Amino-Terminal Pro-B-Type Natriuretic Peptide for Diagnosis and Prognosis in Patients With Renal Dysfunction: A Systematic Review and Meta-Analysis. , 2015, JACC. Heart failure.

[10]  E. Peterson,et al.  Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. , 2015, JAMA.

[11]  R. Califf,et al.  Diuretic response in acute heart failure-an analysis from ASCEND-HF. , 2015, American heart journal.

[12]  M. Vaduganathan,et al.  The vulnerable phase after hospitalization for heart failure , 2015, Nature Reviews Cardiology.

[13]  P. Ponikowski,et al.  Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF , 2014, European journal of heart failure.

[14]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[15]  Adrian F Hernandez,et al.  Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. , 2013, JAMA.

[16]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[17]  P. Ponikowski,et al.  Diuretic response in acute heart failure: clinical characteristics and prognostic significance. , 2013, European heart journal.

[18]  Laura G. Qualls,et al.  Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. , 2013, American heart journal.

[19]  K. Swedberg,et al.  Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. , 2013, European heart journal.

[20]  F. Fedele,et al.  Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations , 2013, Heart Failure Reviews.

[21]  K. Anstrom,et al.  Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.

[22]  G. Fonarow,et al.  Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure). , 2011, The American journal of cardiology.

[23]  P. Ponikowski,et al.  Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.

[24]  C. Yancy,et al.  Use of aldosterone antagonists in heart failure. , 2009, JAMA.

[25]  M. Gheorghiade,et al.  Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review. , 2004, The American journal of cardiology.

[26]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[27]  G. Fonarow,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Circulation.

[28]  J. Ferreira,et al.  Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. , 2014, European journal of internal medicine.